Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Journal:

Journal of Clinical Oncology

Published:

2025-08-02

DOI:

10.1200/jco-25-00236

Affiliations:

11

Authors:

18

Go to article

Institutions	Authors	Share
Starpharma, Australia	6.000000	0.33
The Kinghorn Cancer Centre (TKCC), Australia	2.000000	0.11
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	2.000000	0.11
University of New South Wales (UNSW Sydney), Australia	2.000000	0.11
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)	1.500000	0.08
King's College London (KCL), United Kingdom (UK)	1.500000	0.08
The Newcastle Upon Tyne Hospitals NHS Foundation Trust (NUTH), United Kingdom (UK)	1.000000	0.06
The Christie NHS Foundation Trust, United Kingdom (UK)	0.500000	0.03
The University of Manchester (UoM), United Kingdom (UK)	0.500000	0.03
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	0.500000	0.03
University of Glasgow, United Kingdom (UK)	0.500000	0.03

Interested in Oncology and Carcinogenesis?